ES2072323T3 - Compuestos de piperidina y su preparacion y empleo. - Google Patents

Compuestos de piperidina y su preparacion y empleo.

Info

Publication number
ES2072323T3
ES2072323T3 ES90102913T ES90102913T ES2072323T3 ES 2072323 T3 ES2072323 T3 ES 2072323T3 ES 90102913 T ES90102913 T ES 90102913T ES 90102913 T ES90102913 T ES 90102913T ES 2072323 T3 ES2072323 T3 ES 2072323T3
Authority
ES
Spain
Prior art keywords
preparation
piperidine compounds
compounds
presencephalus
hypocamp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90102913T
Other languages
English (en)
Inventor
Per Sauerberg
Preben H Olesen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DK82589A external-priority patent/DK82589A/da
Priority claimed from DK231589A external-priority patent/DK231589D0/da
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Application granted granted Critical
Publication of ES2072323T3 publication Critical patent/ES2072323T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

EL PRESENTE INVENTO TIENE QUE VER CON LOS COMPUESTOS DE PIPERIDINA TERAPEUTICAMENTE ACTIVOS, SU METODO PARA PREPARARLOS Y LAS COMPOSICIONES FARMACEUTICAS QUE COMPRENDEN LOS COMPUESTOS. LOS NUEVOS COMPUESTOS SON UTILES COMO ESTIMULANTES DE LA FUNCION COGNOSCITIVA DEL PRESENCEFALO Y EL HIPOCAMPO DE LOS MAMIFEROS, Y EN ESPECIAL EN EL TRATAMIENTO DE LA ENFERMEDAD DE ALZHEINER, PROCESOS DOLOROSOS Y EL GLAUCOMA.
ES90102913T 1989-02-22 1990-02-14 Compuestos de piperidina y su preparacion y empleo. Expired - Lifetime ES2072323T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK82589A DK82589A (da) 1989-02-22 1989-02-22 Piperidinforbindelser, deres fremstilling og anvendelse
DK231589A DK231589D0 (da) 1989-05-12 1989-05-12 Piperidinforbindelser og deres fremstilling og anvendelse

Publications (1)

Publication Number Publication Date
ES2072323T3 true ES2072323T3 (es) 1995-07-16

Family

ID=26064725

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90102913T Expired - Lifetime ES2072323T3 (es) 1989-02-22 1990-02-14 Compuestos de piperidina y su preparacion y empleo.

Country Status (22)

Country Link
US (5) US5043345A (es)
EP (2) EP0384285A3 (es)
JP (2) JP2921578B2 (es)
KR (1) KR0163763B1 (es)
CN (1) CN1028105C (es)
AR (1) AR247565A1 (es)
AT (1) ATE123030T1 (es)
AU (2) AU629302B2 (es)
CA (2) CA2010578C (es)
DE (1) DE69019550T2 (es)
DK (1) DK0384288T3 (es)
ES (1) ES2072323T3 (es)
FI (2) FI95704C (es)
GR (1) GR3017062T3 (es)
HU (2) HU221623B1 (es)
IE (1) IE69672B1 (es)
IL (2) IL93352A (es)
NO (2) NO179639C (es)
NZ (1) NZ232615A (es)
PH (1) PH26465A (es)
PT (2) PT93241B (es)
RU (1) RU2042676C1 (es)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0372125A1 (en) * 1988-11-08 1990-06-13 Akzo N.V. Oxazole and thiazole derivatives
US5043345A (en) * 1989-02-22 1991-08-27 Novo Nordisk A/S Piperidine compounds and their preparation and use
US5260311A (en) * 1989-02-22 1993-11-09 Novo Nordisk A/S Piperidine compounds and their use
US5264444A (en) * 1989-02-22 1993-11-23 Novo Nordisk A/S Piperidine compounds and use
US5328925A (en) * 1989-02-22 1994-07-12 Novo Nordisk A/S Piperidine compounds and their use
EP0459568A3 (en) * 1990-05-31 1992-09-30 Merck Sharp & Dohme Ltd. Substituted oxadiazoles and thiadiazoles for use in the treatment of glaucoma and novel compounds having such use
USRE35822E (en) * 1990-08-21 1998-06-09 Novo Nordisk A/S Heterocyclic compounds
US5527813A (en) * 1990-08-21 1996-06-18 Novo Nordisk A/S Heterocyclic compounds and their preparation and use
US5418240A (en) * 1990-08-21 1995-05-23 Novo Nordisk A/S Heterocyclic compounds and their preparation and use
US5376668A (en) * 1990-08-21 1994-12-27 Novo Nordisk A/S Heterocyclic compounds
DK198390D0 (da) * 1990-08-21 1990-08-21 Novo Nordisk As Heterocykliske forbindelser, deres fremstilling og anvendelse
DK198590D0 (da) * 1990-08-21 1990-08-21 Novo Nordisk As Heterocykliske forbindelser, deres fremstilling og anvendelse
DK198490D0 (da) * 1990-08-21 1990-08-21 Novo Nordisk As Heterocykliske forbindelser, deres fremstilling og anvendelse
EP0561913B1 (en) * 1990-11-29 1998-04-01 Allergan, Inc. Use of pyridine derivatives in the treatment of ocular hypertension
EP0492903A1 (en) * 1990-12-21 1992-07-01 MERCK SHARP & DOHME LTD. Substituted pyrazines, pyrimidines and pyridazines for use in the treatment of glaucoma
IE922270A1 (en) * 1991-07-26 1993-01-27 Akzo Nv Pyrazole derivatives
US5641791A (en) * 1991-08-13 1997-06-24 Novo Nordisk A.S Heterocyclic compounds and their preparation and use
US5175166A (en) * 1991-08-27 1992-12-29 The University Of Toledo Muscarinic agonists
WO1993014089A1 (en) * 1992-01-13 1993-07-22 Novo Nordisk A/S Heterocyclic compounds and their preparation and use
US5244906A (en) * 1992-01-23 1993-09-14 Dowelanco Insect control with substituted oxadiazole and thiadiazole compounds
ES2133416T3 (es) * 1992-10-23 1999-09-16 Merck Sharp & Dohme Ligandos de subtipos de receptores de dopamina.
EP0703915B1 (en) * 1993-06-04 2000-09-27 Novo Nordisk A/S Xamoneline tartrate
US5753683A (en) * 1993-08-19 1998-05-19 Novo Nordisk A/S Antipsychotic method
NZ271311A (en) * 1993-08-19 1999-09-29 Novo Nordisk As Pharmaceutical usage of oxa- or thia-diazole-substituted pyridines
US5545638A (en) * 1993-12-21 1996-08-13 Novo Nordisk A/S Method of treating gastrointestinal motility disorders
IL112024A (en) * 1993-12-21 1999-07-14 Novo Nordisk As Pharmaceutical compositions comprising tetrahydropyridine derivatives substituted with oxadiazole or thiadiazole for treating gastrointestinal motility disorders
US5605908A (en) * 1994-10-24 1997-02-25 Eli Lilly And Company Heterocyclic compounds and their use
US5821370A (en) * 1994-10-24 1998-10-13 Eli Lilly And Company Heterocyclic compounds and their preparation and use
US5998404A (en) 1994-10-24 1999-12-07 Eli Lilly And Company Heterocyclic compounds and their use
DK0709094T3 (da) * 1994-10-31 2000-07-10 Lilly Co Eli Tetrahydropyridinoxadiazol- eller thiadiazolforbindelse til behandling af angst
US5726193A (en) * 1994-10-31 1998-03-10 Eli Lilly And Company Method for treating anxiety
US5488056A (en) * 1994-10-31 1996-01-30 Eli Lilly And Company Method for treating anxiety
US5574028A (en) * 1994-10-31 1996-11-12 Eli Lilly And Company Method for treating anxiety
US5484794A (en) * 1994-11-09 1996-01-16 Eli Lilly And Company Method for treating anxiety
US5565475A (en) * 1994-11-08 1996-10-15 Muhlhauser; Mark A. Method of treating urinary bladder dysfunctions with 3-tetrahydropyridine derivatives
US5612351A (en) * 1994-11-08 1997-03-18 Novo Nordisk A/S Method of treating urinary bladder dysfunctions
TW304167B (es) * 1995-01-30 1997-05-01 Lilly Co Eli
US5605701A (en) * 1995-02-17 1997-02-25 Eli Lilly And Company Transdermal formulation
US5763457A (en) 1995-11-13 1998-06-09 Eli Lilly And Company Method for treating anxiety
US5852037A (en) * 1995-11-13 1998-12-22 Eli Lilly And Company Method for treating anxiety
EP0874828A4 (en) * 1995-12-06 1999-09-01 Lilly Co Eli PAIN TREATMENT COMPOSITIONS
NZ324594A (en) * 1995-12-07 1999-09-29 Lilly Co Eli A method and composition for treating pain using a composition comprising an azacyclic azabicyclic or tetrahydropyridine compound and an analgesic
GB9603755D0 (en) * 1996-02-22 1996-04-24 Pfizer Ltd Therapeutic agents
WO1997039753A1 (en) * 1996-04-23 1997-10-30 Eli Lilly And Company Heterocyclic compounds
CA2250472A1 (en) * 1996-04-23 1997-10-30 Steven James Quimby Heterocyclic compounds
ATE250055T1 (de) * 1996-04-24 2003-10-15 Novo Nordisk As Heterozyklische verbindungen, ihre herstellung und ihre anwendung
EP0821957A3 (en) * 1996-08-01 1998-04-22 Eli Lilly And Company Use of 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine (xanomeline) for treating substance abuse
US6043258A (en) * 1996-08-01 2000-03-28 Eli Lilly And Company Method for treating disruptive behavior disorders with xanomeline
ATE213413T1 (de) * 1996-08-01 2002-03-15 Lilly Co Eli Verwendung von 3-(4-hexyloxy-1,2,5-thiadiazol-3- yl)-1,2,5,6-tetrahydro-1-methylpyridin (xanomelin) zur behandlung von bipolaren störungen
US6090829A (en) * 1996-08-01 2000-07-18 Eli Lilly And Company Method for treating excessive aggression
EP0821959A3 (en) * 1996-08-01 1998-09-16 Eli Lilly And Company Use of 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine for treating nicotine withdrawal
EP0821956A1 (en) * 1996-08-01 1998-02-04 Eli Lilly And Company Method for treating disruptive behavior disorders
US6117890A (en) * 1996-08-01 2000-09-12 Eli Lilly And Company Method for treating bipolar disorder
EP0821958A3 (en) * 1996-08-01 1998-07-08 Eli Lilly And Company Use of 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine (xanomeline) for treating excessive aggression
EP0821954A1 (en) * 1996-08-01 1998-02-04 Eli Lilly And Company Method for treating mental retardation
WO1998017214A1 (en) * 1996-10-23 1998-04-30 Eli Lilly And Company Method for treating dementia due to aids
ATE273007T1 (de) 1997-05-29 2004-08-15 Lundbeck & Co As H Behandlung der schizophrenie und der psychose
US6034108A (en) * 1997-07-28 2000-03-07 Eli Lilly And Company Method for treating mental retardation
US6528529B1 (en) 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
US6211204B1 (en) 1999-01-22 2001-04-03 University Of Toledo Muscarinic receptor agonists
US6376675B2 (en) 1999-01-22 2002-04-23 The University Of Toledo Muscarinic receptor agonists
US6096767A (en) * 1999-01-22 2000-08-01 The University Of Toledo Muscarinic receptor agonists
US20040023951A1 (en) * 2001-06-18 2004-02-05 Bymaster Franklin Porter Combination therapy for treatment of psychoses
CA2620333A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
CN1821243B (zh) * 2005-08-30 2010-12-08 北京大学 取代的吡啶类m1受体激动剂、其制备方法及其用途
US7985756B2 (en) 2005-10-21 2011-07-26 Braincells Inc. Modulation of neurogenesis by PDE inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
CN101374836A (zh) * 2005-12-27 2009-02-25 托莱多大学 毒蕈碱激动剂及其使用方法
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
JP2009536669A (ja) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド アンジオテンシン調節による神経新生
MX2008014320A (es) 2006-05-09 2009-03-25 Braincells Inc Neurogenesis mediada por el receptor de 5-hidroxitriptamina.
AU2007292848A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20110294835A1 (en) 2008-05-15 2011-12-01 The Board Of Trustees Of The University Of Illinois Muscarinic Agonists as Cognitive Enhancers
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
WO2011011060A1 (en) 2009-07-22 2011-01-27 Puretech Ventures Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
US10265311B2 (en) 2009-07-22 2019-04-23 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
JP5916746B2 (ja) 2010-11-15 2016-05-11 エージンバイオ， インコーポレイテッド 認知障害を処置するためのピリダジン誘導体、組成物、および方法
US9549928B2 (en) 2011-04-29 2017-01-24 The University Of Toledo Muscarinic agonists as enhancers of cognitive flexibility
CN106068256B (zh) 2013-12-20 2020-10-23 艾吉因生物股份有限公司 用于治疗认知损害的苯并二氮杂*衍生物、组合物和方法
CN113264939A (zh) 2015-06-19 2021-08-17 艾吉因生物股份有限公司 用于治疗认知损害的苯并二氮杂环庚三烯衍生物、组合物和方法
US20180250270A1 (en) 2015-09-11 2018-09-06 Chase Pharmaceuticals Corporation Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
BR112019012821A2 (pt) 2016-12-19 2019-11-26 Agenebio Inc derivados de benzodiazepina, composições e métodos para o tratamento do comprometimento cognitivo
CN112601749B (zh) 2018-06-19 2024-03-26 艾吉因生物股份有限公司 用于治疗认知损害的苯并二氮杂环庚三烯衍生物，组合物和方法
UA128017C2 (uk) 2018-09-28 2024-03-13 Каруна Тереп'Ютікс, Інк. Композиція і спосіб лікування розладу, що послаблюється активацією мускаринових рецепторів (варіанти)
US11534434B2 (en) 2019-11-15 2022-12-27 Karuna Therapeutics, Inc. Xanomeline derivatives and methods for treating neurological disorders
CN115974863A (zh) * 2021-10-14 2023-04-18 南京迈诺威医药科技有限公司 占诺美林衍生物的苹果酸盐、a晶型及其制备方法和用途
US20240132513A1 (en) 2022-08-19 2024-04-25 Agenebio, Inc. Benzazepine derivatives, compositions, and methods for treating cognitive impairment

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ219646A (en) * 1986-03-27 1990-10-26 Merck Sharp & Dohme Oxadiazole derivatives of azacyclics for treating cns disorders
IL83275A (en) * 1986-09-08 1994-02-27 Novo Nordisk As Compounds 1,2, 4-Oxadiazolyl Pipridine Transformed, their preparation and pharmaceutical preparations containing them
US5017618A (en) * 1987-03-16 1991-05-21 University Of Florida Labile derivatives of ketone analogs of 3-substituted-1-alkylamino-2-propanols and their use as beta-adrenergic blockers
GB8714789D0 (en) * 1987-06-24 1987-07-29 Lundbeck & Co As H Heterocyclic compounds
NZ225999A (en) * 1987-09-10 1992-04-28 Merck Sharp & Dohme Azacyclic- or azabicyclic-substituted thiadiazole derivatives and pharmaceutical compositions
IL88156A (en) * 1987-11-13 1997-02-18 Novo Nordisk As Azacyclic compounds their preparation and pharmaceutical compositions containing them
NZ227841A (en) * 1988-02-12 1991-08-27 Merck Sharp & Dohme Heterocyclic compounds with at least two non-condensed five membered rings and pharmaceutical compositions
DK162892C (da) * 1988-07-04 1992-05-11 Novo Nordisk As 1,2,5,6-tetrahydropyridinforbindelser, deres fremstilling og farmaceutiske praeparater indeholdende disse
US5328925A (en) * 1989-02-22 1994-07-12 Novo Nordisk A/S Piperidine compounds and their use
US5260311A (en) * 1989-02-22 1993-11-09 Novo Nordisk A/S Piperidine compounds and their use
US5264444A (en) * 1989-02-22 1993-11-23 Novo Nordisk A/S Piperidine compounds and use
US5043345A (en) * 1989-02-22 1991-08-27 Novo Nordisk A/S Piperidine compounds and their preparation and use
DK198390D0 (da) * 1990-08-21 1990-08-21 Novo Nordisk As Heterocykliske forbindelser, deres fremstilling og anvendelse
DK198490D0 (da) * 1990-08-21 1990-08-21 Novo Nordisk As Heterocykliske forbindelser, deres fremstilling og anvendelse
US5175166A (en) * 1991-08-27 1992-12-29 The University Of Toledo Muscarinic agonists

Also Published As

Publication number Publication date
AU629302B2 (en) 1992-10-01
FI900887A0 (fi) 1990-02-22
IE900504L (en) 1990-08-22
NO179639B (no) 1996-08-12
PH26465A (en) 1992-07-27
NZ232615A (en) 1992-06-25
GR3017062T3 (en) 1995-11-30
US5712297A (en) 1998-01-27
JPH02255679A (ja) 1990-10-16
AU4999790A (en) 1990-08-30
NO900830D0 (no) 1990-02-21
NO179639C (no) 1996-11-20
EP0384288A3 (en) 1991-04-10
FI900886A0 (fi) 1990-02-22
KR910015569A (ko) 1991-09-30
CA2010578C (en) 2000-05-23
EP0384285A3 (en) 1991-04-24
AU4999690A (en) 1990-08-30
NO900831L (no) 1990-08-23
IE69672B1 (en) 1996-10-02
DE69019550D1 (de) 1995-06-29
PT93241A (pt) 1990-08-31
FI95704B (fi) 1995-11-30
CA2010579A1 (en) 1990-08-22
CA2010578A1 (en) 1990-08-22
JP2921578B2 (ja) 1999-07-19
KR0163763B1 (ko) 1998-12-01
US5284859A (en) 1994-02-08
HU221623B1 (hu) 2002-12-28
ATE123030T1 (de) 1995-06-15
AR247565A1 (es) 1995-01-31
NO900830L (no) 1990-08-23
DE69019550T2 (de) 1995-10-05
EP0384288A2 (en) 1990-08-29
CN1028105C (zh) 1995-04-05
US5043345A (en) 1991-08-27
US5041455A (en) 1991-08-20
RU2042676C1 (ru) 1995-08-27
CN1045104A (zh) 1990-09-05
NO900831D0 (no) 1990-02-21
EP0384285A2 (en) 1990-08-29
HU211705A9 (en) 1995-12-28
JPH02255680A (ja) 1990-10-16
DK0384288T3 (da) 1995-10-02
HU900884D0 (en) 1990-05-28
IL93423A0 (en) 1990-11-29
HUT58326A (en) 1992-02-28
PT93241B (pt) 1996-01-31
PT93242A (pt) 1990-08-31
US5559138A (en) 1996-09-24
EP0384288B1 (en) 1995-05-24
IL93352A0 (en) 1990-11-29
FI95704C (fi) 1996-03-11
IL93352A (en) 1994-08-26

Similar Documents

Publication Publication Date Title
ES2072323T3 (es) Compuestos de piperidina y su preparacion y empleo.
ES2124707T3 (es) Compuestos heterociclicos y su preparacion y utilizacion.
ES2170141T3 (es) 4-aminoderivados del acido micofenolico con actividad inmunosupresora.
FI954130A (fi) Heterosykliset yhdisteet ja niiden valmistus ja käyttö
ES2110997T3 (es) 1,2,5,6-tetrahidro-1-metilpiridinas, su preparacion y uso.
ES2186670T3 (es) Derivados de prostaglandina para el tratamiento del glaucoma o la hipertension ocular.
AR003427A1 (es) Péptidos relacionados con dolastatina, procedimiento para prepararlos, composiciones farmacéuticas que los contienen y el uso de los mismos para la preparación de dichas composiciones farmacéuticas.
ES2079075T3 (es) Compuestos heterociclicos y su preparacion y uso.
ES2084339T3 (es) Tetrahidropiridinas e hidroxipiperidinas sustituidas utiles como agentes para el sistema nervioso central.
BR9915951A (pt) Processo para preparação de uma composição farmacêutica para uso como um medicamento antiarritmias com um bloqueio beta adrenérgico controlado, composição farmacêutica, preparação oral e parenteral para tratamento de doenças cardìacas em mamìferos, e, método de tratamento para as mesmas
ES2039408T3 (es) Un procedimiento para preparar un compuesto de tienotriazolodiazepina.
AR016382A1 (es) Uso de un derivado del acido bencil-indazol metoxialcanoico.
ES2062407T3 (es) Compuestos de 2-hidroxi-3-fenoxipropilamino.
MX9401172A (es) Derivados fluorados de 4-aminoandrostadienona, procesamiento para su preparacion y composiciones farmaceuticas que los contienen.
ES2036545T3 (es) Derivados de n-1h-tetrazol-5-il-(anillo de 5 eslabones)-carboxamida, un procedimiento para su preparacion y el uso de los mismos.
ES2055440T3 (es) Derivados del acido quinurenico, su preparacion y composiciones farmaceuticas que los contienen.
FR2381786A1 (fr) Nouveaux aryl-hexafuranosides, leur preparation et leur application en tant que medicaments
MX9300244A (es) Derivados de difluorometilenandrostenona y proceso para su preparacion.
ES2052483T1 (es) Nuevos derivados del 3,3,5-trimetilciclohexanol, su procedimiento de preparacion asi como las composiciones terapeuticas que los contienen.
ECSP951563A (es) Compuestos heterociclicos y su preparacion y uso

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 384288

Country of ref document: ES